Biotech Calendar

The BiotechStockTrader Calendar is a list of biotech companies with near-term catalysts in the form the FDA approvals coming up this month (July 2016)

QURE – Phase I/II – Data from AMT-060 will be presented at the World Federation of Hemophilia on July 27, 2016.

BMRN – NDA – The NDA filing of Cerliponase alfa is estimated for mid-2016.

CCXI – Phase IB – Early response data from CCX872 is due in mid-2016 along with initial PFS data due out in the second half of the year.

CORT – Phase I/II – Mifepristone data is due out in mid-2016.

CYCC – Phase III – Phase III top-line data for Sapacitabine is due in mid-2016, although interim data suggests that the trial will fail.

GWPH – Phase II – Phase II data for GW42004 for Type 2 diabetes is due in late second quarter or early third quarter.

KMDA – Phase II – Phase II data for AAT is due in mid-2016.

KPTI – Phase II – Phase II data for Selinexor is due in mid-2016.

MCRB – Phase II – Phase II data for SER-109 is due in mid-2016.

MRNS – Phase II – Phase II data for Ganaxolone is due in mid-2016.

SCYX – Phase II – Phase II data for SCY-078 is due in July 2016.

THLD – Phase II – Phase II data for Tarloxotinib is due in mid-2016.

TLOG – Phase II – Phase II data for SHAPE is due in mid-2016.